Intranasal DrugDelivery’s Second Act: Strategic Considerations for Developers in 2026 and Beyond
Chelsea
This article was originally published in Contract Pharma. Regulatory momentum, device innovation, and advances in formulation science are repositioning the nasal route as a strategic option for systemic and CNS therapies—provided sponsors address translational and development challenges early. March 2, 2026By: Ted BarrettSr. Director, Translational Research – Pharmacology, Lovelace Biomedical After years of incremental progress, intranasal drug delivery is beginning to show the contours ... Read